Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy with viral vectors.

Neeltje A Kootstra1, Inder M Verma

  • 1Laboratory of Genetics, The Salk Institute, La Jolla, California 92037-1099, USA. kootstra@salk.edu

Annual Review of Pharmacology and Toxicology
|October 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blocking Host Factors IAP and DDX3 Activates HIV-1 Transcription and Increases Apoptosis Sensitivity of HIV-1 Infected Cells.

Pathogens (Basel, Switzerland)·2026
Same author

Refining biomarker-based clustering of cardiovascular inflammatory phenotypes in HIV using Recursive Feature Addition: A comparative evaluation approach.

PLoS computational biology·2026
Same author

Existence of Causation without Correlation in Transcriptional Networks.

bioRxiv : the preprint server for biology·2026
Same author

Transcriptomic Signatures of Immune Suppression and Cellular Dysfunction Distinguish Latent from Transcriptionally Active HIV-1 Infection in Dendritic Cells.

International journal of molecular sciences·2026
Same author

HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir.

eLife·2026
Same author

Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination.

The Journal of infection·2026

Developing effective gene delivery systems is crucial for successful gene therapy. Current viral vectors show promise in clinical trials for genetic disorders, but further development is needed for improved treatments.

Area of Science:

  • Gene Therapy
  • Molecular Biology
  • Virology

Background:

  • Gene therapy success hinges on efficient and safe gene delivery systems.
  • Viral vectors are the primary tools for gene transfer in current research and clinical applications.
  • Extensive evaluation in animal models informs the development of these vectors.

Purpose of the Study:

  • To review the current state of viral vector development for gene therapy.
  • To highlight the importance of efficient gene transfer across diverse tissues.
  • To underscore the need for minimizing pathogenic effects of gene delivery systems.

Main Methods:

  • Review of existing literature on viral vector development and performance.
  • Analysis of data from animal model studies on vector efficiency and pathogenicity.

Related Experiment Videos

  • Examination of results from early-stage clinical trials using viral vectors.

    • Main Results:

    • Various viral vectors, including retroviral, adenoviral, and adeno-associated viral vectors, have been developed.
    • These vectors have demonstrated varying degrees of efficiency and pathogenicity in preclinical studies.
    • Initial clinical trials show encouraging outcomes for genetic disorder correction.

    Conclusions:

    • Viral vectors are foundational for current gene therapy clinical trials.
    • Ongoing research and development are essential to enhance vector performance and safety.
    • Further refinement of gene delivery systems will improve future treatments for hereditary disorders.